Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 14/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.48 |
| ▸ | F2 | P00734 | 11/20 | 0.48 |
| ▸ | PLG | P00747 | 3/20 | 0.38 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.36 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852033 | 0.93 | ST14 (0.49) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL851560 | 0.85 | MRGPRX4 (0.43) | LTA4H | |
| SCHEMBL851255 | 0.85 | ST14 (0.51) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL3786265 | 0.84 | ST14 (0.48) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL851305 | 0.83 | FFAR1 (0.41) | SMPD1LTA4H | |
| SCHEMBL3790587 | 0.83 | ST14 (0.56) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL852041 | 0.82 | ST14 (0.54) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL851813 | 0.81 | ST14 (0.53) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL8509922 | 0.81 | ST14 (0.53) | ST14PRSS1PRSS2PRSS3F2 | |
| SCHEMBL3794040 | 0.81 | ST14 (0.61) | ST14PRSS1PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |